MedTrace Logo

Validation of DaTscan for Detection of Parkinson Disease Related Disorders

NCT02138682 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2014-07-16

No results posted yet for this study

Summary

This investigator initiated trial is designed to measure the accuracy of diagnosis of Parkinson disease through the use of DaTscan. Currently, DaTscan is FDA approved to measure dopamine transporter densities in human tissue. This measurement can assist in distinguishing between Essential Tremor and Parkinsonian Syndromes (idiopathic Parkinson disease, Progressive Supranuclear Palsy, Multi Systems Atrophy, etc). This study will compare both clinical diagnosis of symptoms and the results of the scan to the pathological diagnosis received at time of death. Patients will be registered in the Parkinson Research Institute's brain donation program, receive a clinical diagnosis of Parkinson disease, have their brain scanned using DaTscan, and donate their tissue for research and autopsy purposes. The hypothesis of the study is that DaTscan will diagnosis Idiopathic Parkinson Disease as accurately as a clinician.

Conditions

Interventions

DRUG

l-123 Ioflupane

5 millicuries of Ioflupane

Sponsors & Collaborators

  • Wisconsin Parkinson Association

    collaborator UNKNOWN

  • Medical College of Wisconsin

    collaborator OTHER

  • GE Healthcare

    collaborator INDUSTRY

  • Wisconsin Institute for Neurologic and Sleep Disorders S.C.

    lead INDUSTRY

Principal Investigators

  • Paul A Nausieda, MD · Wisconsin Institute for Neurologic and Sleep Disorders

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02138682 on ClinicalTrials.gov